GOBiolab Obtains Patent Rights for Obesity Treatment Composition Using Korean-Derived Strains
[Asia Economy Reporter Ji Yeon-jin] Gobiolab announced on the 4th that it has acquired a patent for a composition for the prevention and treatment of immune and metabolic diseases using strains independently discovered from Koreans.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- [Breaking] Samsung Labor-Management 'Performance Bonus Negotiations' Fail in Third Mediation... Union Says "General Strike to Proceed as Planned Tomorrow"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This patent utilizes a newly discovered Bacteroides vulgatus strain from Koreans to suppress obesity and metabolic diseases and has immune regulatory functions. It can be applied to products for the prevention, treatment, or improvement of metabolic diseases including obesity.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
